Antibody drug conjugates in Alzheimer's disease: emerging strategies and future directions.

Antibody-drug conjugates (ADCs) are emerging as a targeted therapeutic strategy for Alzheimer's disease (AD), offering precise delivery of disease modifying agents with reduced systemic toxicity. By linking monoclonal antibodies to small-molecule pay…

Preview only. Read the full abstract at the source